100 subject matter experts were surveyed from smaller biotech innovators to gain insight into the dynamics and drivers of the current biologics market.
The biologics CDMO selected for a given product or program is critical to an innovator’s ability to deliver a drug product safely, on time, and on budget.
While crafting a RFP to capture the information innovators need to select a CDMO partner has always been critical; it has grown increasingly complicated.